ScientiaCME Looking forward without losing sight: present and emerging management strategies for neovascular age-related macular degeneration

Details

In this online, self-learning activity:

Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss in older adults and a major driver of vision-related disability in high-income settings. In the United States, an estimated 18.3 million individuals have non–vision-threatening AMD and approximately 1.5 million have vision-threatening disease, creating substantial direct and indirect economic costs for patients, caregivers, and health systems. Late-stage AMD is commonly categorized as geographic atrophy (GA) or neovascular (or “wet”) AMD (nAMD); nAMD is characterized by macular neovascularization with exudation and/or hemorrhage that can rapidly compromise central vision if not controlled. Without timely therapy, vision decline after conversion to late-stage AMD may be clinically meaningful over weeks to months, and missed opportunities for early suppression can translate into avoidable functional loss.

Topics Covered

Faculty introduction and disclosures

• Epidemiology of and risk factors for AMD
• Clinical features of AMD and imaging workflow
• Treatment of neovascular AMD
• Addressing barriers to optimal care

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session, the participant will be able to:

• Employ diagnostic and treatment strategies that account for comorbidities and concurrent therapies in neovascular AMD
• Apply guideline-concordant imaging and diagnostic criteria to evaluate suspected nAMD
• Design individualized nAMD management plans that address response variability, treatment burden, and safety
• Summarize recent pivotal nAMD trial data and how it informs durability, dosing interval, and outcomes
• Use clear, patient-centered language to convey mechanisms and key data for approved and emerging nAMD therapies; Plan interprofessional approaches to screening, monitoring, and supporting treatment adherence in neovascular AMD

Target Audience

HCPs, including comprehensive ophthalmologists; retinal specialists; physician assistants, nurse practitioners, and nurses who practice in ophthalmology; and any other healthcare professionals with an interest in or who clinically encounter patients with AMD.

Additional credit info

ACCME Activity #203749991

ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.